Clinical trial NCT00773071: Added-value of SPECT/CT in Patients Undergoing LM/SL for Gynecological Cancers
Official title: Added-value of SPECT/CT in Patients Undergoing Lymphatic Mapping and Sentinel Lymphadenectomy (LM/SL) for Gynecological Cancers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cervical Cancer
Vulvar Cancer
Keywords: Cervical cancer, vulvar cancer, LM/SL, SPECT/CT
Lead sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Sponsor class: OTHER
Collaborators: name: University of Western Ontario, Canada
First posted: 2008-10-16
Enrollment: 15
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Nodal staging is a key-step in pre-treatment assessment of gynecological cancers. In recent years, lymphatic mapping and sentinel lymphadenectomy (LM/SL) as a minimally invasive pelvic lymph nodes staging has been successfully evaluated in women with early stage of vulvar cancer, cervical cancer, and endometrial cancer. Such a technique may offer several valuable advantages: a) it is readily applicable in clinical routine using a safe, inexpensive, and reproducible protocol; b) it may help to avoid the cost and the morbidity of unnecessary lymphadenectomy in the majority of cases with uninvolved sentinel lymph nodes; c) it has the potential to guide the surgeon to nodal regions that are not routinely dissected (i.e. pre-sacral, para-aortic nodes) and to identify micro-metastases that would have been ignored otherwise; d) it also offers the basis for sophisticated pathological analysis to detect sub-microscopic nodal metastases using either immunohistochemical or molecular biological techniques.

So far, within the abdomen and the pelvis, the LM/SL technique alone is often blinded to the accurate localization of SLNs. The integration of computed tomography (CT) to single photon emission computed tomography (SPECT) devices in a single gantry (SPECT/CT) has allowed a significant gain in terms of diagnostic accuracy and anatomic precision; clinical examples include malignant melanoma, head and neck cancer, breast cancer, and bladder cancer. In a seminal series of 26 patients with cervical cancer (Zhang et al., 2006), SPECT/CT was recently found superior to conventional planar imaging for detection of SLN and accurate localization. A more recent study (Kushner al., 2007) has also highlighted the technical feasibility and the clinical added-value of a low-dose SPECT/CT in a series of 20 patients with early stage cervical cancer (IA2-IIA) who underwent LM/SL.

In the light of the encouraging data from literature and our own preliminary clinical experience, we hypothesized that the use of LM/SL plus SPECT/CT may be of clinical interest in patients with gynecological cancers.

Detailed description: This clinical trial is aimed at assessing the utility of a minimally invasive surgery preoperatively guided by a new nuclear medicine imaging procedure called SPECT/CT. In patients suffering from an early stage of gynecological cancer with no clinical evidence of lymph node involvement, there is theoretically no reason to perform systematically an aggressive lymphadenectomy as demonstrated for other types of lymphophilic cancers such as malignant melanoma, breast cancer, and head and neck cancer.

We plan to follow a well known and safe procedure in Nuclear Medicine called lymphatic mapping and sentinel lymphadenectomy (LM/SL). The patient will be injected by the gynecologist referee in the department of Nuclear Medicine. These injections consist of a radioactive tracer routinely used in Nuclear Medicine, which allows the detection of the first nodes draining the primary tumor. The so-called sentinel lymph node (SLN) may be different from the lymph nodes anatomically predefined. As well demonstrated for other cancers, including those mentioned above, we hypothesized that the histological status of the SLN may accurately reflect the histological status of the entire nodal basin. If this assumption is clinically validated, the minimally invasive procedure may avoid the cost and the morbidity of unnecessary complete lymph node dissections in the majority of patients with uninvolved SLNs.

The originality of this clinical trial also relies upon the use of a new hybrid imaging device called SPECT/CT, which allows the ability to obtain in a single study both functional and anatomical information. This is critical to precisely guide the surgeon in his task. No contrast medium will be injected during this study. The radiation exposure remains within the limits accepted worldwide; for instance, the CT dose index (CTDI) will be 3.0 mGy, which is in the order of the yearly natural background radiation exposure (\< 2mSv).

In this clinical trial, all patients will be treated according to the standard of care currently applied for gynecological cancers. Therefore, either the hysterectomy or the vulvectomy will be followed by a complete lymph node dissection (CLND).

Overall, the research protocol will be carried out in a 1-day protocol including the SPECT/CT guided LM/SL and the CLND.

Eligibility criteria: Inclusion Criteria:

* Patients with histologically proven gynecological cancers
* Patients with FIGO IA2 and IB1 cervical cancers
* Cervical cancer patients will be scheduled for radical hysterectomy and pelvic lymph node dissection
* Patients with FIGO IB and II vulvar cancers and those of patients with FIGO III with clinically negative regional lymph nodes
* Vulvar cancer patients will be scheduled for vulvectomy and inguinal lymph node dissection
* Informed consent signed by the patient, the gynaecologist, and the nuclear medicine physician referees

Exclusion Criteria:

* Patients with no histological evidence of gynecological cancer
* Patient with regionally advanced disease or metastatic disease
* Patients with clinically and/or radiologically evident regional lymph node metastases
* Patients who are not scheduled for radical surgery and lymph node dissection
* Patients with physical and/or psychological contraindications
* Recent study in Nuclear Medicine with long half-time isotopes (i.e. T ½ \>48h; 111In, 67Ga, 201Tl, 131I ) performed within 1 week preceding the LM/SL
* Pregnant or lactating patients

Primary outcomes:
measure: Sensitivity, predictive value, anatomic localization, and impact on management of SPECT/CT guided LM/SL versus CLND
timeFrame: 6 months -1 year
Secondary outcomes:
measure: Patient tolerability and operating time for SPECT/CT guided LM/SL versus CLND
timeFrame: 6 months - 1 year
Other outcomes:
Locations:
city: London
country: Canada
facility: 375, South Street Hospital - Dpt. of Nuclear Medicine
state: Ontario
Study officials:
affiliation: The University of Western Ontario - Nuclear Medicine
name: Irina Rachinsky, MD, MSc
role: PRINCIPAL_INVESTIGATOR
affiliation: The University of Western Ontario - Nuclear Medicine
name: Jean-Luc Urbain, MD, PhD
role: STUDY_CHAIR
affiliation: The University of Western ontario - Gynaecology
name: Monique Bertrand, MD, PhD
role: STUDY_DIRECTOR
affiliation: The University of Western Ontario -Pathology
name: Helen Ettler, MD
role: STUDY_DIRECTOR
References:
citation: Kushner DM, Connor JP, Wilson MA, Hafez GR, Chappell RJ, Stewart SL, Hartenbach EM. Laparoscopic sentinel lymph node mapping for cervix cancer--a detailed evaluation and time analysis. Gynecol Oncol. 2007 Sep;106(3):507-12. doi: 10.1016/j.ygyno.2007.04.031. Epub 2007 Jun 8.
citation: Zhang WJ, Zheng R, Wu LY, Li XG, Li B, Chen SZ. [Clinical application of sentinel lymph node detection to early stage cervical cancer]. Ai Zheng. 2006 Feb;25(2):224-8. Chinese.
citation: Belhocine T, Kridelka F, Thille A, De Barsy C, Foidart-Willems J, Hustinx R, Rigo P. Staging of primary cervical cancers: the role of nuclear medicine. Crit Rev Oncol Hematol. 2003 Jun;46(3):275-84. doi: 10.1016/s1040-8428(03)00027-1.
citation: Van der Zee AG, Oonk MH, De Hullu JA, Ansink AC, Vergote I, Verheijen RH, Maggioni A, Gaarenstroom KN, Baldwin PJ, Van Dorst EB, Van der Velden J, Hermans RH, van der Putten H, Drouin P, Schneider A, Sluiter WJ. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008 Feb 20;26(6):884-9. doi: 10.1200/JCO.2007.14.0566.
citation: Levenback CF. How safe is sentinel lymph node biopsy in patients with vulvar cancer? J Clin Oncol. 2008 Feb 20;26(6):828-9. doi: 10.1200/JCO.2007.14.7124. No abstract available.
citation: Levenback CF. Status of sentinel lymph nodes in cervical cancer. Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S18-9. doi: 10.1016/j.ygyno.2007.07.039. Epub 2007 Aug 29. No abstract available.
citation: van de Lande J, Torrenga B, Raijmakers PG, Hoekstra OS, van Baal MW, Brolmann HA, Verheijen RH. Sentinel lymph node detection in early stage uterine cervix carcinoma: a systematic review. Gynecol Oncol. 2007 Sep;106(3):604-13. doi: 10.1016/j.ygyno.2007.05.010. Epub 2007 Jul 12.
citation: Benedet JL, Bender H, Jones H 3rd, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2000 Aug;70(2):209-62. No abstract available.
citation: Martinez A, Zerdoud S, Mery E, Bouissou E, Ferron G, Querleu D. Hybrid imaging by SPECT/CT for sentinel lymph node detection in patients with cancer of the uterine cervix. Gynecol Oncol. 2010 Dec;119(3):431-5. doi: 10.1016/j.ygyno.2010.08.001. Epub 2010 Sep 6.
citation: Pandit-Taskar N, Gemignani ML, Lyall A, Larson SM, Barakat RR, Abu Rustum NR. Single photon emission computed tomography SPECT-CT improves sentinel node detection and localization in cervical and uterine malignancy. Gynecol Oncol. 2010 Apr;117(1):59-64. doi: 10.1016/j.ygyno.2009.12.021. Epub 2010 Feb 1.
citation: Diaz-Feijoo B, Perez-Benavente MA, Cabrera-Diaz S, Gil-Moreno A, Roca I, Franco-Camps S, Fernandez MS, Garcia-Jimenez A, Xercavins J, Martinez-Palones JM. Change in clinical management of sentinel lymph node location in early stage cervical cancer: the role of SPECT/CT. Gynecol Oncol. 2011 Mar;120(3):353-7. doi: 10.1016/j.ygyno.2010.12.336. Epub 2011 Jan 6.
citation: Freudenberg LS, Gortz E, Hagen C, Harms E, Koska WW, Marlowe RJ, Shadouh S, Stock C. Lymphatic mapping using SPECT/CT in vulvar carcinoma. Clin Nucl Med. 2010 Dec;35(12):950-2. doi: 10.1097/RLU.0b013e3181f9de96. No abstract available.
citation: Kobayashi K, Ramirez PT, Kim EE, Levenback CF, Rohren EM, Frumovitz M, Mar MV, Gayed IW. Sentinel node mapping in vulvovaginal melanoma using SPECT/CT lymphoscintigraphy. Clin Nucl Med. 2009 Dec;34(12):859-61. doi: 10.1097/RLU.0b013e3181becdaf.
citation: Belhocine TZ, Prefontaine M, Lanvin D, Bertrand M, Rachinsky I, Ettler H, Zabel P, Stitt LW, Sugimoto A, Urbain JL. Added-value of SPECT/CT to lymphatic mapping and sentinel lymphadenectomy in gynaecological cancers. Am J Nucl Med Mol Imaging. 2013;3(2):182-93. Epub 2013 Mar 8.